Inhaled insulin - What went wrong

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 1, 2009, Pages 24-25

  Mitri, Joanna ^a   Pittas, Anastassios G ^b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN;

CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRY COUGH; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG CANCER; LUNG FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY;

ADMINISTRATION, INHALATION; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; RISK ASSESSMENT;

EID: 57649195453     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet1007     Document Type: Short Survey

References (6)

1. Berenson A (2007) Weak sales prompt Pfizer to cancel diabetes drug [http://www.nytimes.com/2007/10/19/business/19pfizer.html?ref=business] (accessed 1 October 2008)
2. Ceglia L et al. (2006) Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145: 665-675
3. Exubera® labeling update [http://www.fda.gov/medwatch/safety/2008/ Exubera_DHCP.pdf]
4. Davis TM and Davis WA (2007) An assessment of eligibility for inhaled insulin (Exubera): the Fremantle Diabetes Study. Diabetes Care 30: 360-361
5. Freemantle N et al. (2005) Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28: 427-428
6. Eisenberg JM (1999) Ten lessons for evidence-based technology assessment. JAMA 282: 1865-1869